Forwarded by Subcommittee to Full Committee by Voice Vote.
This bill extends a program that funds research and speeds up access to treatments for ALS (a fatal nerve disease also called Lou Gehrig's disease) for five more years, through 2031. It also adds new requirements for the FDA to check on how clinical trials are going and to publish a report on its plans for fighting ALS and similar rare brain diseases. If this passes, federal funding for ALS research grants continues instead of expiring, and there is more oversight of how that money is being used.
About 30,000 Americans live with ALS, a disease that is always fatal and currently has no cure. This bill keeps federal research dollars flowing for five more years and pushes the FDA to track whether funded clinical trials are actually making progress toward new treatments.